Skip to content


    DEA Class; Rx

    Common Brand Names; Factive

    • Fluoroquinolones

    Acts by inhibiting both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. Because of this dual mechanism, MIC values remain in the susceptible range for some double mutants (eg, S pneumoniae)

    Indicated for Acute Exacerbations of Chronic Bronchitis

    Limitations-of-use: Reserve fluoroquinolones for patients who do not have other available treatment options for acute bacterial exacerbation of chronic bronchitis

    Pneumonia (community-acquired)

    All drugs or conditions that prolong QT interval

    Documented hypersensitivity to gemifloxacin or other fluoroquinolones

    • Diarrhea (5%)
    • Headache (4%)
    • Nausea (4%)
    • Rash (4%)
    • Transaminases increased (1-4%)
    • Abdominal pain (2%)
    • Dizziness (2%)
    • Vomiting (2%)
    • Neutropenia (1%)
    • Platelets increased (1%)
    • Thrombocythemia (1%)
    • GGT increased (1%)
    • Peripheral neuropathy
    • Photosensitivity
    • Tendon rupture

    May prolong QT interval

    May cause maculopapular rash

    Although not reported in gemifloxacin clinical trials, convulsions, increased intracranial pressure (including pseudotumor cerebri), and toxic psychosis reported with other fluoroquinolones

    Peripheral neuropathy: Sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias, and weakness reported; peripheral neuropathy may occur rapidly after initiating and may potentially become permanent

    In prolonged therapy, perform periodic evaluations of organ system functions (eg, renal, hepatic, hematopoietic); adjust dose in renal function impairment; superinfections may occur with prolonged or repeated antibiotic therapy

    Not drug of first choice in pediatrics due to increased incidence of adverse events compared to controls, including arthropathy; no data exist for dose for pediatric patients with renal impairment (ie, CrCl <50 mL/min)

    Fluoroquinolones are associated with increased risk of tendinitis and tendon rupture in all ages, this risk is further increased in older patients usually over 60 yr, in patients taking corticosteroids, and in patients with kidney, heart, or lung transplants (see Black Box Warnings)

    May exacerbate muscle weakness in patients with myasthenia gravis; avoid fluoroquinolones with known history of myasthenia gravis

    Limited available human data with use in pregnant women are insufficient to inform an associated risk of miscarriages, major birth defects, and/or adverse maternal or fetal outcomes; based on animal studies with gemifloxacin, therapy, may cause fetal harm; in animal reproduction studies, administration of drug to pregnant mice and rabbits during the period of organogenesis produced embryofetal toxicity at exposures up to 2 and 3 times, respectively, the maximum recommended human dose; advise pregnant women of potential risk to fetus

    There is no data on presence of gemifloxacin in human milk, effects on milk production, on breastfed infant


    Acute Exacerbations of Chronic Bronchitis

    320 mg PO qDay x5 days

    Pneumonia (community-acquired)

    (Multidrug resistant S. pneumoniae; K. pneumoniae; M. catarrhalis): 320 mg PO qDay x7 days

    (S. pneumoniae; M. pneumoniae; H. influenzae; C. pneumoniae): 320 mg PO qDay x 5days


    Safety and efficacy not established



    • 320mg